The beneficial effect of MR inhibition in patients with heart failure was confirmed by other randomized clinical trials, such as the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) [7,8]. Here, NR3C2 is linked to heart failure.